Volitional Dysfunction in Self-control Failures and Addictive Behaviors

September 6, 2023 updated by: Technische Universität Dresden
The aim of this project is to elucidate whether impairments of cognitive control, performance-monitoring, and value-based decision-making and dysfunctional interactions between underlying brain systems are mediating mechanisms and vulnerability factors for daily self-control failures and addictive disorders.

Study Overview

Detailed Description

Failures of self-control during conflicts between long-term goals and immediate desires are a key characteristic of many harmful behaviors, including unhealthy eating habits, lack of exercise and problematic substance use, which often have adverse personal consequences and incur great societal costs. The project aims to elucidate neurocognitive mechanisms mediating deficient self-control, both in daily self-control failures and in substance use disorders and behavioral addictions, which are characterized by a loss of control despite awareness of adverse consequences. A prospective cohort study was launched using a multi-level approach that combines (i) a comprehensive clinical assessment, (ii) behavioral task batteries assessing cognitive control and decision-making functions, (iii) task-related and resting state fMRI, and (iv) Smartphone-based ecological momentary assessment of daily self-control failures. From a representative community sample, three groups of participants were recruited (each n = 100; age 20 - 26) with (a) symptoms of non-substance related and (b) substance-related addictive disorders and (c) syndrome-free controls. Participants are invited to yearly clinical follow-up assessments and further multi-level assessments 3 and 6 years after initial recruitment. Results obtained so far (until 06/2020) provide converging evidence that task performance as well as brain activity in monitoring, control, and valuation networks is reliably associated with the propensity to commit real-life self-control failures. Results support a process model, according to which deficient performance-monitoring leads to an insufficient recruitment of control networks, which attenuates the impact of long-term goals on neural value signals and increases the likelihood of self-control failures. In the final funding period (until 06/2024), the clinical follow-up period will be extended to 7 years. In addition, stress markers will be assessed as possible moderators of self-control. With the cross-lagged panel design it is expected to make a substantial contribution to the central unresolved question whether dysfunctions of cognitive control are causally involved in the development and trajectories of self-control failures and addictive behaviors, as well as to the disputed question of communalities and differences between different addictive disorders. Thereby, the project will to contribute to mechanism-based models of self-control impairments as a foundation for improved prevention and therapy.

Study Type

Observational

Enrollment (Actual)

338

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Dresden, Germany, 01062
        • Technische Universität Dresden, Faculty of Psychology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 27 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

The age range was 19 to 27 years at baseline. As expected for our sampling procedure, the addictive disorder severity was mainly mild (baseline 62%) and moderate (baseline 28%).

Description

Inclusion Criteria (at baseline):

  1. age 19-27
  2. fulfill the criteria for one of three groups (SUD, ND, controls)
  3. written informed consent

Exclusion Criteria (at baseline):

  1. no written informed consent or limited ability to understand the questionnaires and tasks
  2. disorders that might influence cognition or motor performance (e.g. craniocerebral injury)
  3. magnetic resonance contraindications
  4. current treatment for mental disorders
  5. current use of psychotropic medication or substances
  6. lifetime psychotic symptoms, bipolar disorder, or other SUD or ND not under study
  7. major depression, somatoform, anxiety, obsessive compulsive, or eating disorders within the last 4 weeks

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Substance use disorder (SUD) group
In the substance use disorder (SUD) group, participants had a diagnosis of alcohol and/or tobacco use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) but no lifetime non-substance-related addictive disorder (ND).
Non-substance-related addictive disorder (ND) group
In the non-substance-related addictive disorder (ND) group, participants were included who fulfilled two or more criteria for a DSM-5 gambling disorder or for an addictive behavior related to Internet use (not for gambling, gaming, or shopping), gaming, or shopping assessed with adapted criteria from DSM-5 substance use disorder (SUD). Participants in the ND group had no lifetime SUD.
Control group
The control participants had no current or lifetime substance use disorder (SUD) or non-substance-related addictive disorder (ND).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in addictive disorder severity
Time Frame: At baseline and 1, 2, 3, 4, 5, 6, 7 years after baseline
Changes in number of fulfilled criteria according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5)
At baseline and 1, 2, 3, 4, 5, 6, 7 years after baseline
Changes in quantity and frequency of addictive behaviors
Time Frame: At baseline and 1, 2, 3, 4, 5, 6, 7 years after baseline
Changes in quantity and frequency of addictive behaviours, which are combined into a quantity-frequency index.
At baseline and 1, 2, 3, 4, 5, 6, 7 years after baseline
Changes in cognitive control abilities
Time Frame: At baseline and 3 and 6 years after baseline
The Cognitive Control Task Battery of the Collaborative Research Center (CRC) 940 with nine executive function tasks (Stroop, AX continuous performance, color-shape, stop signal, letter memory, number-letter, go-nogo, 2-back, category switch) is used to derive a latent variable representing individual differences in general executive functioning (GEF). For the latent variable modelling error rates and reaction times from the tasks were combined, were appropriate, into inverse efficiency scores (IESs).
At baseline and 3 and 6 years after baseline
Changes in impulsive decision-making
Time Frame: At baseline and 3 and 6 years after baseline
The Value-Based Decision-Making (VBDM) battery of the Collaborative Research Center (CRC) 940 including four decision-making tasks with a Bayesian adaptive algorithm was used to adaptively assess impulsive decision-making. For the delay and probability discounting tasks, a hyperbolic value function was used describing that the subjective values of delayed (or probabilistic) reward decline hyperbolically according to the discounting rate k. For the mixed gambles task, a simple linear function was used in which loss aversion (λ) is the relative weighting of losses to gains in the participant's. Individuals with higher impulsive decision-making are assumed to display higher k values in the delay discounting task, lower k values in probability discounting tasks, and lower λ values in the mixed gambles task.
At baseline and 3 and 6 years after baseline
Changes in neural correlates of response inhibition
Time Frame: At baseline and 3 and 6 years after baseline
Blood oxygenation level dependent (BOLD) responses in tasks measuring response inhibition (Go/Nogo, Stroop) using 3 Tesla functional magnetic resonance imaging (fMRI).
At baseline and 3 and 6 years after baseline
Changes in neural correlates of error monitoring
Time Frame: At baseline and 3 and 6 years after baseline
BOLD responses in a task measuring error monitoring (Stroop) using 3 Tesla fMRI.
At baseline and 3 and 6 years after baseline
Changes in neural correlates of value-based decision-making
Time Frame: At baseline and 3 and 6 years after baseline
BOLD responses in a task measuring value-based decision-making using 3 Tesla fMRI.
At baseline and 3 and 6 years after baseline
Changes in structural brain characteristics
Time Frame: At baseline and 3 and 6 years after baseline
Gray matter volume, cortical thickness and white matter properties in theoretically motivated regions of interest (e.g., right inferior frontal gyrus (rIFG), ventromedial prefrontal cortex (vmPFC), anterior cingulate cortex (ACC), anterior insula (aINS)) using 3 Tesla structural MRI.
At baseline and 3 and 6 years after baseline
Changes in real-life self-control
Time Frame: At baseline and 3 and 6 years after baseline
Everyday self-control was assessed using an Ecological Momentary Assessment (EMA) protocol adapted from Hofmann, Baumeister, Förster, and Vohs (2012). Self-control was defined as enactment of desires in conflict-laden situations.
At baseline and 3 and 6 years after baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intelligence
Time Frame: At baseline
As control variable we assessed the intelligence quotient (IQ) using the Wechsler Intelligence Test for Adults (WIE).
At baseline
Personality
Time Frame: At baseline
As moderator variable we assessed the NEO Five Factor Inventory (NEO-FFI; outcomes are the sum scores).
At baseline
Positive and negative affect
Time Frame: At baseline
As moderator variable we assessed the Positive and Negative Affect Schedule (PANAS; outcomes are the sum scores).
At baseline
Changes in the action and state orientation
Time Frame: At baseline and 3 and 6 years after baseline
As moderator variable we assessed the Action-State Orientation Scale (ACS-90; outcomes are the sum scores).
At baseline and 3 and 6 years after baseline
Changes in impulsivity
Time Frame: At baseline and 3 and 6 years after baseline
As moderator variable we assessed the Barratt Impulsiveness Scale (BIS-11; outcome is the sum score).
At baseline and 3 and 6 years after baseline
Changes in self control
Time Frame: At baseline and 3 and 6 years after baseline
As moderator variable we assessed the Brief Self-Control Scale (BSCS; outcome is the sum score).
At baseline and 3 and 6 years after baseline
Changes in chronic stress
Time Frame: At baseline and 3 and 6 years after baseline
As moderator variable we assessed the Trier Inventory for Chronic Stress (TICS; outcome is the sum score).
At baseline and 3 and 6 years after baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Thomas Goschke, Prof. Dr., Technische Universitat Dresden
  • Principal Investigator: Michael N. Smolka, Prof. Dr., Technische Universitat Dresden
  • Principal Investigator: Gerhard Bühringer, Prof. Dr., Technische Universitat Dresden

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2014

Primary Completion (Estimated)

December 31, 2023

Study Completion (Estimated)

June 30, 2024

Study Registration Dates

First Submitted

July 27, 2020

First Submitted That Met QC Criteria

July 30, 2020

First Posted (Actual)

August 5, 2020

Study Record Updates

Last Update Posted (Actual)

September 8, 2023

Last Update Submitted That Met QC Criteria

September 6, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • SFB940 C01
  • Project number 178833530 (Other Grant/Funding Number: Deutsche Forschungsgemeinschaft (DFG))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data and analytic codes within publications will be shared via the Open Science Framework (OSF). Final archiving of the participant data will be conducted with the Open Access Repository and Archive at the Technische Universität Dresden (OpARA).

IPD Sharing Time Frame

Data and analytic codes within publications will be shared from the time of publications. Final archived data will be shared after the study is completed in 2024.

IPD Sharing Access Criteria

Open Access

IPD Sharing Supporting Information Type

  • ANALYTIC_CODE

Study Data/Documents

  1. Official study group website
  2. English description of the Collaborative Research Centre
    Information comments: The study is conducted within the Collaborative Research Centre 940 funded by the Deutsche Forschungsgemeinschaft (DFG).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tobacco Use Disorder

  • Washington University School of Medicine
    National Cancer Institute (NCI); National Institutes of Health (NIH)
    Completed
    Smoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditions
    United States
  • Johns Hopkins University
    National Institute on Drug Abuse (NIDA)
    Recruiting
    Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence
    United States
  • Harvard School of Public Health (HSPH)
    Beacon Communities; The Community Builders
    Enrolling by invitation
    Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Second Hand Tobacco Smoke
    United States
  • University of California, San Francisco
    National Institute on Minority Health and Health Disparities (NIMHD)
    Completed
    Smoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Smoking, Tobacco | Smoking, Cigarette
    United States
  • University of California, San Francisco
    Tobacco Related Disease Research Program
    Completed
    Smoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Smoking, Tobacco | Smoking, Cigarette
    United States
  • New York State Psychiatric Institute
    Terminated
    Smoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Nicotine Dependence | Cigarette Smoking | Tobacco Dependence | Nicotine Use Disorder | Smoking, Cigarette
    United States
  • Rutgers, The State University of New Jersey
    National Institute on Drug Abuse (NIDA)
    Completed
    Schizophrenia | Schizoaffective Disorder | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation
    United States
  • University of Pennsylvania
    Food and Drug Administration (FDA)
    Completed
    Tobacco Use | Tobacco Dependence
    United States
  • University of Kansas Medical Center
    Completed
    Tobacco Use Disorder/Cigarette Smoking
    United States
  • Ottawa Hospital Research Institute
    Completed
    Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence

Clinical Trials on Observational study without interventions

3
Subscribe